Lyell Immunopharma Inc. has announced that new clinical and translational data from the Phase 1/2 trial of rondecabtagene autoleucel (ronde-cel, LYL314) for the treatment of aggressive large B-cell lymphoma (LBCL) will be presented at the 67th American Society of Hematology $(ASH)$ Annual Meeting and Exposition. Ronde-cel is a dual-targeting CD19/CD20 CAR T-cell therapy candidate designed to improve complete response rates and duration of response compared to existing CD19-targeted CAR T-cell therapies. The U.S. FDA has granted ronde-cel Regenerative Medicine Advanced Therapy (RMAT) and Fast Track designations for relapsed and/or refractory diffuse LBCL in the third- or later-line setting. The presentations, scheduled for December 7, 2025, will include data on the durability of response as well as the post-infusion expansion and memory phenotype of CD62L-enriched T cells in treated patients. Lyell is continuing patient enrollment in the PiNACLE single-arm registration trial and is initiating a randomized controlled trial comparing ronde-cel to approved CD19 CAR T-cell therapies in the second-line setting.